Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|94|4|363-367

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.4, 2015-04, pp. : 363-367

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-03 ,pp. : 122-127

Karger

Access to resources Recommend Favorite

Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines

By Neelakantan Pratap   Apperley Jane F  

Clinical Practice, Vol. 10, Iss. 3, 2013-05 ,pp. : 283-291

Future Medicine

Access to resources Recommend Favorite

More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-09 ,pp. : 18-19

Karger

Access to resources Recommend Favorite

Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 105-109

Karger

Access to resources Recommend Favorite

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

By Wu Eric Q.   Guerin Annie   Yu Andrew P.   Bollu Vamsi K.   Guo Amy   Griffin James D.  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2861-2869

Informa Healthcare

Access to resources Recommend Favorite